Related Experiment Video
Updated: Jul 10, 2026
09:28
One-step Metabolomics: Carbohydrates, Organic and Amino Acids Quantified in a Single Procedure
Published on: June 26, 2010
[Comparative presentation of current economic evaluation studies for phenylketonuria screening]
Gesundheitswesen (Bundesverband Der Arzte Des Offentlichen Gesundheitsdienstes (Germany))
|July 17, 1999
Summary
Phenylketonuria (PKU) screening offers significant economic value, with cost-benefit ratios ranging from 1:1.2 to 1:9.25. Standardizing economic evaluations is crucial for accurate comparisons in newborn screening programs.
Area of Science:
- Public Health
- Medical Economics
- Genetics
Background:
- Newborn screening programs are essential for early detection of inborn errors of metabolism.
- Phenylketonuria (PKU) is a key target for newborn screening due to its treatable nature.
- Economic evaluations are vital for assessing the value and sustainability of screening initiatives.
Purpose of the Study:
- To systematically review and assess the economic value of PKU screening within newborn screening frameworks.
- To identify and analyze differences and similarities across international economic evaluation studies of PKU screening.
- To discuss future trends and technological advancements in newborn screening.
Main Methods:
- Conducted a systematic review of seven international studies on the economic value of PKU screening.
- Examined studies for variations and commonalities in methodology and findings.
- Analyzed cost-benefit ratios and factors influencing economic outcomes.
Main Results:
- The cost-benefit ratios of PKU screening programs varied significantly, ranging from 1:1.2 to 1:9.25.
- Observed differences are attributable to variations in PKU incidence and methodological approaches in economic evaluations.
- Highlighted the need for standardization in economic evaluation methodologies for greater consistency.
Conclusions:
- PKU screening demonstrates a favorable economic return, justifying its implementation in newborn screening.
- Methodological standardization is essential for reliable and comparable economic assessments of screening programs.
- Emerging technologies hold potential for future advancements and expanded applications in newborn screening.
Related Concept Videos
02:46Genetic Screens
Genetic screens are tools used to identify genes and mutations responsible for phenotypes of interest. Genetic screens help identify individuals or a group of people at risk of developing genetic diseases and help them with early intervention, targeted therapy, and reproductive options.
Forward genetic screens
Forward or “classical” genetic screens involve creating random mutations in an organism’s DNA using radiation, mutagens, or insertion of additional bases, which result in visible changes...
Forward genetic screens
Forward or “classical” genetic screens involve creating random mutations in an organism’s DNA using radiation, mutagens, or insertion of additional bases, which result in visible changes...
01:20Inborn Errors of Metabolism
Phenylketonuria (PKU) is a protein metabolism disorder characterized by high blood levels of the amino acid phenylalanine. This results from a mutation in the gene responsible for phenylalanine hydroxylase, an enzyme that converts phenylalanine into tyrosine. When this enzyme is deficient, phenylalanine builds up in the blood, leading to symptoms such as vomiting, rashes, seizures, growth deficiency, and severe mental retardation. An early diagnosis and a diet restricting phenylalanine intake...
01:26Pharmacokinetic Models: Comparison and Selection Criterion
Physiological and compartmental models are valuable tools used in studying biological systems. These models rely on differential equations to maintain mass balance within the system, ensuring an accurate representation of the dynamic processes at play.
Physiological models take a detailed approach by considering specific molecular processes. They can predict drug distribution, metabolism, and elimination changes, providing a comprehensive understanding of how drugs interact with the body.
Physiological models take a detailed approach by considering specific molecular processes. They can predict drug distribution, metabolism, and elimination changes, providing a comprehensive understanding of how drugs interact with the body.
01:24Pharmacokinetics in Pediatric Patients: Drug Metabolism
In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses a challenge in...
01:22Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess the...
01:24Serum Studies: Renal Function Tests
Renal function tests are crucial for assessing kidney health, monitoring disease progression, and evaluating the kidneys' efficiency in waste elimination, fluid balance, and electrolyte regulation. These tests offer critical insights into kidney function, even though routine measurements may appear normal until there is a significant decline in the glomerular filtration rate or GFR. Typically, signs of kidney impairment only become evident when the GFR falls to about 50% of its normal level.